Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Receivables: 2012-2024

Historic Change in Receivables for Coherus Oncology (CHRS) over the last 11 years, with Dec 2024 value amounting to -$149.3 million.

  • Coherus Oncology's Change in Receivables rose 154.64% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.2 million, marking a year-over-year decrease of 223.12%. This contributed to the annual value of -$149.3 million for FY2024, which is 199.12% down from last year.
  • Per Coherus Oncology's latest filing, its Change in Receivables stood at -$149.3 million for FY2024, which was down 199.12% from $150.7 million recorded in FY2023.
  • Coherus Oncology's 5-year Change in Receivables high stood at $150.7 million for FY2023, and its period low was -$149.3 million during FY2024.
  • Over the past 3 years, Coherus Oncology's median Change in Receivables value was -$13.1 million (recorded in 2022), while the average stood at -$3.9 million.
  • As far as peak fluctuations go, Coherus Oncology's Change in Receivables plummeted by 323.83% in 2021, and later surged by 1,254.48% in 2023.
  • Over the past 5 years, Coherus Oncology's Change in Receivables (Yearly) stood at $15.2 million in 2020, then slumped by 323.83% to -$34.1 million in 2021, then skyrocketed by 61.68% to -$13.1 million in 2022, then spiked by 1,254.48% to $150.7 million in 2023, then crashed by 199.12% to -$149.3 million in 2024.